^
    Back
    Association details:
    Biomarker:NTRK2 fusion
    Cancer:Pancreatic Cancer
    Drug:Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Metastatic Pancreatic Cancer: ASCO Guideline Update

    Published date:
    08/05/2020
    Excerpt:
    Recommendations…Treatment Options After First-Line Therapy…In patients with tumors harboring NTRK fusions, treatment with larotrectinib or entrectinib is recommended…
    DOI:
    10.1200/JCO.20.01364 Journal of Clinical Oncology
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Sarcoma)
    New
    Title:

    New sarcoma drug approved for use in England

    Excerpt:
    We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-GI 2021
    Title:

    SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset

    Published date:
    07/04/2021
    Excerpt:
    As of July 20, 2020, 18 patients with metastatic TRK fusion-positive GI cancer were enrolled...The other tumor types were cholangiocarcinoma (n=3), pancreatic (n=2), appendiceal (n=1), esophageal (n=1), and hepatocellular carcinoma (n=1)….In patients with TRK fusion-positive GI cancer, larotrectinib demonstrated rapid responses with high survival rates and a favorable safety profile.
    DOI:
    10.1016/j.annonc.2021.05.053
    Trial ID:
    NAVIGATE
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Larotrectinib efficacy and safety in adult TRK fusion cancer patients.

    Excerpt:
    TRK fusions involved NTRK1 (40%), NTRK2 (2%), and NTRK3 (57%)….Larotrectinib demonstrated robust tumor-agnostic efficacy and a favorable safety profile in adult pts with TRK fusion cancer.
    DOI:
    10.1200/JCO.2019.37.15_suppl.3122